Mehrara et al. has shown that Th2 inhibition, via the monoclonal antibody blockade of IL-4 and IL-13 antibodies, has potential for improving the clinical response to lymphedema and resulting dermal dysfunction [79]. The gene discussed is IL4; the disease is lymphedema.